## 5<sup>th</sup> International Conference on

## **HIV/AIDS, STDs and STIs**

November 13-14, 2017 Las Vegas, Nevada, USA

## CD4+ T lymphocytes and viral load in patients with AIDS debut who receive antiretroviral therapy

Hernandez Requejo D<sup>1</sup>, Perez Avila J<sup>1</sup> and Carr Perez A<sup>2</sup>
<sup>1</sup>Instituto de Medicina Tropical Pedro Kouri, Cuba
<sup>2</sup>Centro de Inmunologia Molecular, Cuba

**Background:** AIDS premiere is a form of presentation the illness caused by HIV characterized by alteration of the patient's general state, waste syndrome, opportunist's infections, neoplasia and neurological alterations.

**Objective:** CD4+ T lymphocytes levels and of viral load in patient with AIDS premiere and antiretroviral therapy, were studied to the beginning and one year after the treatment.

Methods: A cross sectional prospective observational study was conducted in 55 HIV/AIDS patients, attended in the Medical Services offered by IPK during one year, which had to the beginning of the treatment CD4+ T lymphocytes counts less to  $200c\acute{e}l/\mu L$  and high viral load.

**Results:** It was observed that there was an average rise of 262 cel per  $\mu$ L in the CD4+ T-lymphocytes, as well as an average fall of 60 452 cp/ $\mu$ L in viral load one year after the antiretroviral treatment.

**Conclusions:** With this study, we can conclude that after a year of therapy, the values of CD4+ T cells recovered and the viral load levels diminished in the evaluated patients. The results of this study confirm the benefits of antiretroviral therapy, particularly for patient with AIDS premiere

dayme@ipk.sld.cu